TSH抑制治疗对分化型甲状腺癌患者骨密度的影响:系统综述与荟萃分析
结果显示,绝经后女性腰椎骨密度显著降低(加权均数差-0.03;95%CI -0.05至-0.02),全髋有类似趋势;绝经前女性腰椎和股骨颈骨密度显著增加;男性各部位骨密度无显著关联。
要点
- 绝经后女性接受TSH抑制治疗与腰椎骨密度降低显著相关。
- 绝经前女性TSH抑制治疗与腰椎和股骨颈骨密度增加相关。
- 男性患者TSH抑制治疗与各部位骨密度无显著关联。
核心结论
- 观察性研究证据提示,接受TSH抑制治疗的绝经后女性存在骨密度降低风险,应关注分化型甲状腺癌幸存者的长期骨骼安全。
主要发现
- 绝经后女性TSH抑制治疗组腰椎骨密度显著降低,加权均数差-0.03(95%CI -0.05至-0.02),全髋呈类似趋势。
- 绝经前女性TSH抑制治疗组腰椎骨密度显著增加,加权均数差0.04(95%CI 0.02至0.06),股骨颈骨密度增加0.02(95%CI 0.01至0.04)。
- 男性患者TSH抑制治疗与任何部位骨密度均无显著关联。
临床怎么用
- 对分化型甲状腺癌术后接受TSH抑制治疗的绝经后女性,应关注骨密度监测与骨骼健康管理。
局限性
- 证据来源于观察性研究,可能存在混杂偏倚;未报告各研究的具体TSH抑制目标及持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Because subclinical hyperthyroidism increases the risk of osteoporosis and fractures, concerns are growing about the long-term skeletal safety of TSH suppression therapy after total thyroidectomy in patients with differentiated thyroid cancer (DTC). OBJECTIVE: We aimed to determine the effect of TSH suppression therapy on bone mineral density (BMD) in DTC patients. METHODS: We searched PubMed, Embase, the Cochrane library, and other sources. Eligible observational studies included DTC patients who underwent TSH suppression therapy and BMD measurement. Two independent reviewers extracted data on the studies' characteristics and outcomes and determined their risk of bias. Data were extracted from each study for postmenopausal/premenopausal women's and men's lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD and summed using a random-effects meta-analysis model. The weighted mean differences with 95% CIs are expressed for the differences in outcome measurements between groups. RESULTS: Seventeen studies (739 patients and 1085 controls) were included for quantitative analysis. In postmenopausal women, TSH suppression therapy showed a significant decrease in LS BMD (-0.03; -0.05, -0.02), and a similar trend was seen in TH. In premenopausal women, TSH suppression therapy significantly increased LS BMD (0.04; 0.02, 0.06) and FN BMD (0.02; 0.01, 0.04). In men, there was no significant association between TSH suppression therapy and BMD at any site compared with the controls. CONCLUSION: Evidence from observational studies suggests that postmenopausal women treated with TSH suppression therapy are at risk for lower BMD. Attention should be paid to long-term skeletal safety in DTC survivors.
引用
- Ku EJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021. PMID: 34302730. doi:10.1210/clinem/dgab539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。